concerase

Concerase is a prescription medication used to treat chronic kidney disease (CKD) in adults with a specific type of protein buildup in the blood called *beta-2 microglobulin amyloidosis*. This condition often occurs in patients undergoing long-term dialysis, particularly those on hemodialysis. The drug works by reducing levels of beta-2 microglobulin, a waste product that accumulates in the body when kidney function declines.

Developed by Kyowa Kirin, Concerase is administered as a subcutaneous injection, typically given three times per week. It contains recombinant human neutral alpha-glucosidase, an enzyme that helps break down excess beta-2 microglobulin. Clinical studies have shown that Concerase can improve symptoms associated with beta-2 microglobulin amyloidosis, such as joint pain and stiffness, by reducing the buildup of amyloid deposits in tissues.

Common side effects of Concerase may include injection site reactions, such as redness, swelling, or itching. More serious adverse effects, though rare, could involve allergic reactions or worsening of kidney function. As with any medication, healthcare providers monitor patients closely to ensure safety and efficacy.

Concerase was approved by the U.S. Food and Drug Administration (FDA) in 2018 after demonstrating positive results in clinical trials. It is not a cure for chronic kidney disease but rather a targeted treatment for a specific complication associated with long-term dialysis. Patients considering Concerase should discuss its benefits and risks with their nephrologist or healthcare provider.